The CJEU attempted to clarify the meaning of “protected by a basic patent” in Teva v Gilead, but practitioners and in-house counsel say it raises more questions than it has answered including a new test that is not clear
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
Patrick assists with editorial agenda management, and regularly reports on patent-related issues, including FRAND, supplementary protection certificates and patent eligibility, as well as trade secrets. He also chairs industry events and produces conference newspapers.